Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy

Investigative Ophthalmology and Visual Science

Volumn 37, Issue 11, 1996, Pages 2318-2325

  Berger, Adam S ^a,d   Cheng, Cheng Kuo ^a   Pearson, P Andrew ^a   Ashton, Paul ^b   Crooks, Peter A ^c   Cynkowski, Tadaeusz ^c   Cynkowska, Gravina ^c   Jaffe, Glenn J ^a  

^a DUKE UNIVERSITY   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c University of Kentucky   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antimetabolites; corticosteroids; drug delivery; proliferative vitreoretinopathy; retinal detachment

Indexed keywords

DEXAMETHASONE; FLUOROURACIL; TRIAMCINOLONE ACETONIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINA DETACHMENT; SKIN FIBROBLAST; VITREORETINOPATHY; VITREOUS BODY; WOUND HEALING;

ANIMALS; ANTIMETABOLITES; DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; FEMALE; FLUOROURACIL; GLUCOCORTICOIDS; MALE; RABBITS; RETINAL DETACHMENT; TRIAMCINOLONE; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 0029848924     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Machemer R. Proliferative vitreoretinopathy (PVR): A personal account of its pathogenesis and treatment. Invest Ophthalmol Vis Sci. 1988;29:1771-1783.
2. Rachal WF, Burton TC. Changing concepts of failures after retinal detachment surgery. Arch Ophthalmol. 1979;97:480-483.
3. The Silicone Study Group. Proliferative vitreoretinopathy. Am J Ophthalmol. 1985;99:593-595.
4. Sunalp M, Wiedemann P, Sorgente N, Ryan SJ. Effects of cytotoxic drugs on proliferative vitreoretinopathy in the rabbit cell injection model. Curr Eye Res. 1984;3:619-623.
5. Khawly JA, Saloupis P, Hatchell DL, Machemer R. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. Graefe's Arch Clin Exp Ophthalmol. 1991;229:464-467.
6. Lemor M, Yeo JH, Glaser BM. Oral colchicine for the treatment of experimental traction retinal detachment. Arch Ophthalmol. 1986;104:1226-1229.
7. Wiedemann P, Kirmani M, Santana M, Sorgente N, Ryan SJ. Control of experimental massive periretinal proliferation by daunomycin: Dose response relation. Graefe's Arch Clin Exp Ophthalmol. 1983;220:233-235.
8. Wiedemann P, Sorgente N, Bekhor C, Patterson R, Tran T, Ryan SJ. Daunomycin in the treatment of experimental proliferative vitreoretinopathy: Effective doses in vitro and in vivo. Invest Ophthalmol Vis Sci. 1985;26:719-725.
9. Cheng CK, Berger AS, Pearson PA, Ashton P, Jaffe GJ. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest Ophthalmol Vis Sci. 1995;36:442-53.
10. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained release ganciclovir implant: A randomized clinical trial. Arch Ophthalmol. 1994;112:1531-1539.
11. Smith TJ, Pearson PA, Blandford DL, et al. Intravitreal sustained release ganciclovir. Arch Ophthalmol. 1992; 110:255-258.
12. Ophir A, Blumenkranz M, Claflin AJ. Experimental intraocular proliferation and neovascularization. Am J Ophthalmol. 1982;94:450-457.
13. Ophir A. Prevention of experimental massive peri-retinal proliferation by 5-fluorouracil. Metab Pediatr Syst Ophthalmol. 1983;7:109-113.
14. Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol. 1980;89:131-136.
15. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980;90:810-816.
16. Ruhmann A, Berliner D. Effect of steroids on growth of mouse fibroblasts in vitro. Endocrinology. 1965; 76:916-927.
17. Chandler DB, Hida T, Sheta S, Proia AD, Machemer R. Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment. Graefe's Arch Clin Exp Ophthalmol. 1987;225:259-265.
18. Stahl JG, Miller DB, Conway BP, Campochiaro PA. Dexamethasone and indomethacin attenuate cryopexy induced breakdown of the blood-retinal barrier. Graefe's Arch Clin Exp Ophthalmol. 1987;225:418-420.
19. Charteris DG, Hiscott P, Grierson I, Lightman SL. Proliferative vitreoretinopathy: Lymphocytes in epiretinal membranes. Ophthalmology. 1992;99:1364-1367.
20. Charteris DG, Hiscott P, Robey HL, Gregor ZJ, Lightman SL, Grierson I. Inflammatory cells in proliferative vitreoretinopathy subretinal membranes. Ophthalmology. 1993;100:43-46.
21. Little BC, Limb GA, Meager A, et al. Cytokines in proliferative vitreoretinopathy. ARVO Abstracts. Invest Ophthalmol Vis Sci. 1991;32:768.
22. Limb GA, Little BC, Meager A, et al. Cytokines in proliferative vitreoretinopathy. Eye. 1991;5:686-693.
23. Schleimer RP. An overview of glucocorticoid anti-inflammatory actions. Eur J Clin Pharmacology. 1993; 45:S3-S7.
24. Lee SW, Tsou AP, Chan H, et al. Glucocorticoids selectively inhibit the transcription of the interleukin 1β gene and decrease the stability of interleukin 1β mRNA. Proc Natl Acad Sci USA. 1988;85:1204-1208.
25. Arya SK, Wong-Staal F, Gallo RC. Dexamethasone-mediated inhibition of human T cell growth factor and gamma-interferon messenger RNA. J Immunol. 1984;133:273-276.
26. Blumenkranz MS, Ophir A, Claflin AJ, Hajek A. Fluorouracil for the prevention of massive periretinal proliferation. Am J Ophthalmol. 1982;94:458-467.
27. Blumenkranz M, Ophir A, Claflin A. A pharmacologic approach to non-neoplastic intraocular proliferation. ARVO Abstracts. Invest Ophthalmol Vis Sci. 1981;20:200.
28. Jarus G, Blumenkranz M, Hernandez E, Sossi N. Clearance of intravitreal fluorouracil: Normal and aphakic vitrectomized eyes. Ophthalmology. 1985;92:91-96.
29. Stern WH, Lewis GP, Erickson PA, et al. Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy. Am J Ophthalmol. 1983;96:33-42.
30. Stern WH, Guerin CJ, Erickson PA, Lewis GP, Anderson DH, Fisher SK. Ocular toxicity of fluorouracil after vitrectomy. Am J Ophthalmol. 1983;96:43-51.
31. Rootman J, Tisdall J, Gudauskas G, Ostry A. Intraocular penetration of subconjunctivally administered 14C-fluorouracil in rabbits. Arch Ophthalmol. 1979; 97:2375-2378.
32. Ophir A. Further observations on the prevention of experimental proliferative vitreoretinopathy by 5-fluorouracil. Ophthalmic Res. 1991;23:128-132.
33. Rubsamen PE, Davis PA, Hernandez E, O'Grady GE, Cousins SW. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch Ophthalmol. 1994;112:407-413.
34. Montera T, Ogura Y, Honda Y, Wada R, Hyon SH, Ikada Y. Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest Ophthalmol Vis Sci. 1991;32:1785-1790.
35. Peyman GA, Conway M, Khoobehi B, Soike K. Clearance of microsphere-entrapped 5-fluorouracil and cytosine arabinoside from the vitreous of primates. Int Ophthalmol. 1992;16:109-113.
36. Giordano GG, Refojo MF, Arroyo MH. Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR. Invest Ophthalmol Vis Sci. 1993;34:2743-2751.